Reading Hospital
Acute Care Hospitals · Voluntary non-profit - Private
420 S 5th Avenue
West Reading, PA 19611
- Emergency services
- Medicare overall rating: 4 of 5 stars
At a glance
- Clinicians who list this hospital
- 1,416
- Physicians (MD and DO)
- 900
- Residents and fellows in training (full-time equivalents, fiscal year 2025)
- 251
- Medical groups
- 15+
Quality and patient experience
- Medicare overall rating (of 5)
- 4
- Patient survey rating (of 5)
- 3
- Patients who would definitely recommend it (national average 71%)
- 64%
Compared with the national rate
| Measures | Better | Same | Worse |
|---|---|---|---|
| Deaths after treatment | 3 | 5 | 0 |
| Safety of care (infections, complications) | 1 | 6 | 1 |
| Readmissions and return visits | 0 | 9 | 2 |
Number of Medicare quality measures where this hospital’s rate is statistically better than, the same as (no different from), or worse than the national rate.
What patients said
- Doctors communicated well 2 of 5 stars
- Nurses communicated well 3 of 5 stars
- Explained medicines 2 of 5 stars
- Discharge information 2 of 5 stars
- Clean 4 of 5 stars
- Quiet at night 2 of 5 stars
From 445 patient surveys (HCAHPS), period ending 09/30/2025.
Medicare “birthing-friendly” hospital: takes part in a maternity care quality program and follows recommended safety practices.
Source: CMS Care Compare (Hospital General Information; Patient survey HCAHPS). Ratings describe the hospital overall, not individual doctors.
Physicians by specialty
- Internal Medicine 170
- Family Medicine 150
- Anesthesiology 47
- Cardiology 42
- Emergency Medicine 37
- Radiology 34
- OB-GYN (Obstetrics & Gynecology) 32
- Neurology 27
- Orthopedic Surgery 26
- Gastroenterology 25
- General Surgery 25
- Hospitalist 20
- Ophthalmology 19
- Urology 17
- Pulmonology 17
- Physical Medicine & Rehabilitation (PM&R) 15
- Hematology & Oncology 15
- Nephrology (Kidney) 15
- Pathology 12
- Endocrinology & Diabetes 12
- Psychiatry 12
- Radiation Oncology 9
- Infectious Disease 9
- Interventional Radiology 8
- ENT (Otolaryngology) 8
- Pain Medicine 8
- Plastic Surgery 7
- Rheumatology 7
- Sports Medicine 7
- Dermatology 6
- Interventional Cardiology 6
- Neurosurgery 6
- Cardiac Electrophysiology 5
- Vascular Surgery 5
- Medical Oncology 5
- Retina Specialist 4
- Geriatric Medicine 4
- Cardiothoracic Surgery 4
- Hospice & Palliative Medicine 3
- Colorectal Surgery 3
- Hand Surgery 3
- Critical Care Medicine 3
- Trauma Surgery 3
- Allergy & Immunology 3
- Urogynecology 2
- Addiction Medicine 2
- Gynecologic Oncology 2
- Hematology 2
- Preventive Medicine & Public Health 1
- Sleep Medicine 1
- Occupational Medicine 1
- Heart Failure & Transplant Cardiology 1
- Pediatric Pulmonology 1
- Maternal-Fetal Medicine (High-Risk Pregnancy) 1
Other clinicians
Medical groups whose clinicians work here
- Tower Health Medical Group 557
- Phoenix Rehabilitation and Health Services Inc 257
- Reading Hospital 185
- Phoenixville Clinic Company LLC 83
- Keystone Rehabilitation Systems Inc 70
- St Joseph Medical Group 64
- Pottstown Clinic Company LLC 59
- Tower Health Urgent Care, LLC 55
- H2 Rehabilitation Extension Services LLC 45
- Regional Gastroenterology Associates of Lancaster, LTD. 36
- Penn State Health Medical Group LLC 33
- Lehigh Valley Physician Group 32
- Integrated Medical Group P C 26
- Keystone Orthopaedic Specialists,llc 24
- Pottstown Medical Specialists Inc 23
Number of each group’s clinicians who list this hospital.
Industry-funded research here
Drug and device companies reported $530,314 in research payments to this hospital in 2025 for 23 studies.
- A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC · $94,600 - A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
Genentech, Inc. · $68,969 - Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC
Genentech, Inc. · $66,630 - A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Beone Medicines Ltd. · $64,126 · Recruiting - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC · $30,021 - A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study)
EMD Serono, Inc. · $26,920 - A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Daiichi Sankyo Inc. · $26,651 · Active, not recruiting - A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms
Astellas Pharma Global Development · $23,646 - A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
Janssen Research & Development, LLC · $21,627 - Roche Cancer Screening Collection Study
Genentech, Inc. · $20,163 - Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. · $19,035 - A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous St…
Janssen Research & Development, LLC · $15,064
From CMS Open Payments research payments to this hospital as a teaching hospital. Payments to affiliated universities or research foundations are reported under those names. All industry-funded trials →
Other hospitals in the same county
Sources: CMS Hospital General Information and Doctors and Clinicians Facility Affiliation (Care Compare), CMS certification number 390044. Counts are clinicians who list this hospital with Medicare; they include part-time and visiting clinicians and aren’t staff totals. Residents and beds are from the hospital’s Medicare cost report. Ratings are Medicare’s, not ours.